Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
12
Number of overlapping holdings
26.1%
% of IDNA's 51 holdings also in CANC
24.5%
% of CANC's 49 holdings also in IDNA
Overlap by Weight
Sector Drift (IDNA minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in IDNA |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
REVOLUTION MEDICINES, INC. | 4.4% | 6.3% | 4.4% |
 |
ASTRAZENECA PLC | 5.3% | 4.3% | 4.3% |
|
EXELIXIS INC | 5.3% | 3.9% | 3.9% |
|
ARCELLX, INC. | 3.6% | 2.7% | 2.7% |
|
MERCK & CO. INC. | 3.9% | 2.6% | 2.6% |
Position Highlights (Non-Overlapping Exposures)
IDNA Overweight Relative to CANC
 |
BEIGENE, LTD. | 5.9% |
|
GSK PLC | 5.6% |
 |
SANOFI-AVENTIS | 5.6% |
 |
ROCHE HOLDING LTD | 5.5% |
|
SPRINGWORKS THERAPEUTICS, INC. | 5.3% |
 |
TAKEDA PHARMACEUTICAL CO LTD | 5.2% |
 |
GENMAB A/S | 4.7% |
 |
BIONTECH SE SPONSORED ADR | 4.0% |
|
INCYTE CORP | 3.3% |
|
BIOCRYST PHARMACEUTICALS INC | 3.3% |
IDNA Underweight Relative to CANC
|
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% |
|
ELI LILLY & CO | -4.8% |
|
NOVARTIS AG | -4.3% |
|
BRIDGEBIO PHARMA, INC. | -4.3% |
|
NUVALENT, INC. CLASS A | -3.9% |
|
SUMMIT THERAPEUTICS INC | -3.9% |
|
BRISTOL-MYERS SQUIBB CO | -3.8% |
|
GENMAB A/S SPONSORED ADR | -3.5% |
|
ZAI LAB LTD. UNSPONSORED ADR | -3.1% |
 |
MERUS N.V. | -3.1% |